Last update April 25, 2022
Compatible
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
4-[2-(1-Methylamino-2-nitrovinylamino)ethylthiomethyl]thiazol-2-ylmethyl(dimethyl)amine; N-[2-(2-Dimethylaminomethylthiazol-4-ylmethylthio)ethyl]-N′-methyl-2-nitrovinylidenediamine is Nizatidine in Chemical name.
Is written in other languages:4-[2-(1-Methylamino-2-nitrovinylamino)ethylthiomethyl]thiazol-2-ylmethyl(dimethyl)amine; N-[2-(2-Dimethylaminomethylthiazol-4-ylmethylthio)ethyl]-N′-methyl-2-nitrovinylidenediamine belongs to this group or family:
Main tradenames from several countries containing 4-[2-(1-Methylamino-2-nitrovinylamino)ethylthiomethyl]thiazol-2-ylmethyl(dimethyl)amine; N-[2-(2-Dimethylaminomethylthiazol-4-ylmethylthio)ethyl]-N′-methyl-2-nitrovinylidenediamine in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 70 - 94 | % |
Molecular weight | 331 | daltons |
Protein Binding | 35 | % |
VD | 0.8 - 1.5 | l/Kg |
Tmax | 3 | hours |
T½ | 1 - 2 | hours |
Theoretical Dose | 0.08 | mg/Kg/d |
Relative Dose | 1.59 | % |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by Academy of Breastfeeding Medicine - 2015 of United States of America
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
Nizatidine is a histamine H2 antagonist with actions and uses similar to those of cimetidine. It inhibits gastric acid secretion and pepsin production. It is used in peptic ulcer and gastroesophageal reflux. Oral or parenteral administration once or twice daily.
It is excreted in breast milk in a clinically insignificant amount and no problems have been observed in the infant whose mother had taken it. (Obermeyer 1990)
Several medical societies, experts and expert consensus, consider the use of this medication to be safe or very probably safe during breastfeeding. (Hale, Briggs 2015, Rowe 2013, Mahadevan 2006, Richter 2005, Nice 2000, Lee 1993)
Famotidine and Nizatidine are excreted into milk but in less proportion than Cimetidine or Ranitidine, which have been proposed as alternative to during lactation. (Rowe 2013, Nice 2000, Hagemann 1998, Lee 1993)